Peter the Bridge, Saint Petersburg, Russia

News from NEOMED

NEOMED Therapeutics 1 names Dr. Frank Giles as Chief Medical Officer

April 10th, 2018 |Announcement| No Comments
Montreal, Quebec, Canada April 10th, 2018 – NEOMED Therapeutics 1 Inc. (NT1), a recently formed company dedicated to advancing novel, orally bioavailable epigenetic dual inhibitors for the targeted treatment of cancer today announced the appointment of Francis J. Giles, MB, MD, FRCPI, FRCPath to the newly created posit

Read complete news

NEOMED Institute Launches NEOMED Therapeutics 1 Inc. to fund and develop a dual BET inhibitor anticancer therapy pipeline with NEO2734, an oral dual BET and CBP/P300 inhibitor, as lead compound

February 28th, 2018 |Announcement| No Comments
  • Christine Lennon named President & CEO
  • IND Qualifying Toxicology Studies Initiated for NEO2734
  • Funding sought to fund:
  1. Phase 1/2 Studies for NE02734
  2. Preclinical Dual BET/SMARCA4 Discovery Program
  3. Clinical Bioma

    Read complete news

ARTELO BIOSCIENCES AND THE NEOMED INSTITUTE ENTER INTO AN EXCLUSIVE GLOBAL OPTION AND LICENSE AGREEMENT

January 30th, 2018 |Announcement| No Comments

Artelo to advance NEOMED's NEO1940 novel, peripherally restricted, CB1/CB2 agonist, clinic-ready drug candidate for the treatment of patients suffering from cancer and anorexia/weight loss associated with cancer

La Jolla, CA, USA / Montreal, QC, Canada - January 30, 2018

Read complete news

NEO6860 Phase II Data to be Presented at the American College of Rheumatology’s Annual Meeting

November 22nd, 2017 | No Comments
- An analgesic effect demonstrated - - No increase in body temperature nor change in heat pain perception - Montreal, October 30, 2017 - The NEOMED Institute announced today that it will present a poster on the Phase II data for its lead program NEO6860 during the American College of Rheumatology’s A

Read complete news

© 2018 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia